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Abstract The cytotoxic effect of the new potential intercalating 
anticancer drug oracin was studied on Burkitt's lymphoma cell 
line that overexpressed bcl-2 (BL bcl-2) and a control 
transfectant without the bcl-2 gene (BL SV2). Oracin showed a 
marked cytostatic effect on both BL SV2 and BL bcl-2 cells. 
IC50, as measured by the MTT assay, was approx. 5-times 
greater for BL bcl-2 cells (5.0 μιηοΐ/l) than for BL SV2 cells (1.0 
μpiιοΐ/ΐ). There was no significant increase in apoptosis after 24 h 
of treatment with oracin (1.0 μιηοΙ/l) in both cell lines. However, 
after 48 h from the removal of oracin in BL SY2 culture the 
levels of apoptotic and secondary necrotic cells increased to 20 
and 37%, respectively. In contrast, BL bcl-2 cells treated in a 
similar manner showed only basal levels of apoptotic and 
secondary necrotic cells. Analysis of the cell cycle profiles 
showed a significant increase of S and G2/M phases of the cell 
cycle in both cell lines after 6 h of drug treatment (1.0 μιηοΙ/1). 
The cells were arrested in G2/M phase of the cell cycle after 24 h, 
with no significant changes in cell viability. After 72 h, the viable 
BL SV2 cells were still in G2/M, however, the viability of this 
culture had fallen to approx. 5%. Flow cytometry analysis of the 
DNA content revealed the presence of a 'sub-G2' region, which 
represented the apoptotic cells. The BL SV2 cells died after 72 h 
while they were in the G2/M phase. Although the treated BL bcl-
2 cells were similarly arrested in the G2/M phase, they 
nevertheless remained with a relatively high viability (68%). 
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1. Introduction 
Oracin is a novel anticancer agent of the idenoisoquinoline 
chemical group and it is both structurally and pharmacologi-
cally related to the clinically used anti-cancer agent mitoxan-
tron (Novatron). The pharmacological, biochemical and tox-
icological characterisation of oracin has been reported by 
Melka [1]. The report indicated that oracin has a significant 
cytotoxicity against a wide spectrum of tumor and leukaemia 
cells both in vitro and in vivo. The planar fundamental struc-
ture of the compound is typical for intercalating antitumor 
agents (anthracyclines, e.g. adriamycin-like drugs and/or an-
thracenediones, e.g. mitoxantrone-like agents). The main ad-
vantage of oracin is the lack of cardiotoxicity which is a dose-
limiting adverse effect of the doxorubicin-like drugs. There is 
also a possibility of its oral administration. 
Treatment of tumor cells with cytotoxic agents or with io-
nising radiation usually results in the breakdown of the cell 
cycle machinery. The subsequent decision of the treated cell 
'to die or not to die' is the outcome of the balance of promot-
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ing and protecting factors in which the capacity of DNA 
repair plays a crucial role [2]. Diverse anti-cancer agents 
may induce a mode of death which has characteristics of 
'programmed' cell death or apoptosis [3]. Apoptosis is a proc-
ess whereby intrinsic or extrinsic stimuli activate a molecular 
programme to implement a specific series of events that cul-
minate in cell death. The entry of a cell into apoptosis can be 
restricted to a particular phase of the cell cycle [4,5], although 
this cell cycle dependence does not appear to be a general 
process [6]. Moreover, circumstantial evidence of the induc-
tion of apoptosis due to damage to the cell cycle or to DNA 
integrity and the presence of many oncogenes that promote 
cell cycle progression also inducing apoptosis has implied the 
existence of a direct linkage between the two antagonistic 
processes [7]. 
It is known that the bcl-2 gene plays an important role in 
the regulation of apoptosis [8]. The bcl-2 gene product is a 
membrane-associated GTP-binding protein that has been 
shown to inhibit apoptosis triggered by a variety of stress 
stimuli, including serum deprivation, radiation and cytotoxic 
agents [9-14]. It is well documented that bcl-2 becomes de-
regulated in tumor cells [4] which may constitute a barrier to 
the success of cancer therapy. Therefore, we studied in vitro 
the protective effect of bcl-2 on cell cycle arrest induced cell 
death in Burkitt's lymphoma cells by the cytotoxic agent ora-
cin. 
2. Materials and methods 
All reagents, except fetal calf serum (Gibco Ltd), were from Sigma 
Ltd. Oracin was provided by the Research Institute for Pharmacy and 
Biochemistry, Prague (Czech Republic). 
The cell lines, Burkitt's lymphoma transfected with control (BL 
SV2) and bcl-2 (BL bcl-2) plasmids, were kindly provided by Dr. 
CD. Gregory (Department of Immunology, University of Birming-
ham, UK). Details of the transfection protocols have been described 
by Milner et. al. [15]. Cells were cultured in RPMI 1640 containing 
10% fetal calf serum, at 37°C in a humid atmosphere of 5% C02/air. 
2.1. Cytotoxicity assay 
Different concentrations of oracin were added to the cells at a 
density of 6X105 cells/ml (concentration of DMSO was maximally 
1% v/v). After 24 h incubation in 5% CO2, incubator samples were 
analysed by standard MTT assay as described by Al-Rubeai [16]. The 
IC50 values of oracin were then calculated for both BL SV2 and BL 
bcl-2 cell lines. 
2.2. Apoptotic response 
Cells suspension were mixed with an equal volume of staining solu-
tion containing 10 μg/ml acridine orange and 10 μ^piύ propidium 
iodide as described by Simpson et. al. [14]. The percentages of viable, 
apoptotic and necrotic cells were determined in an improved Neu-
bauer rhodium-coated haemocytometer under a fluorescence micro-
scope. Results were expressed as a proportion of the total cell number 
(%), established by nucleus morphology and propidium iodide exclu-
sion. 
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Fig. 1. (A,B) Cytotoxic effect of oracin on Burkitt's lymphoma (BL) cells. Cells were treated with different concentrations of the drug for 24 h 
and analysed by the MTT assay. 
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Fig. 2. (A,B) Effect of 0, 1, and 10 umol/1 oracin on growth of BL cells. Cells were treated with oracin for 24 h at day 1. On day 2 the cells 
were washed and incubated in fresh medium, bcl-2, BL transfected with bcl-2; SV2, BL transfected control. 
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Fig. 3. (A,B) Percentage of viable, apoptotic and necrotic BL cells. Non-fixed cells were stained with acridine orange and propidium iodide. 
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2.3. Cell cycle and cell size analysis 
BL cells were inoculated into 20-ml T-flasks (with viable cell density 
3X105 cells/ml). After 24 h incubation in CO2 incubator different 
concentrations of oracin were added. Samples of cell density approx. 
1X106 cells/ml were removed at intervals, spun down (1000 rpm, 
5 min), washed once with PBS and fixed with cold 70% ethanol and 
kept at 4°C. After 24 h the samples were centrifuged as before, 
washed once with PBS and incubated with 100 μΐ of 0.5 mg/ml RNase 
for 30 min. Cells were washed once with PBS and resuspended in 0.5 
ml of PBS and 40 ul of 0.5 mg/ml propidium iodide. The samples were 
analysed on a Coulter Epics Elite flow cytometer. 
3. Results and discussion 
MTT assay was used to determine the cytotoxic effect 
(IC50) of oracin on BL SV2 cells and BL bcl-2 cells (Fig. 
1A,B). Drug treatment for 24 h led to IC50 values of 1 ±0.1 
and 5 ± 0.2 umol/l for BL SV2 and BL bcl-2 cells, respectively. 
An approx. 5-times higher value of IC50 for BL cells with bcl-
2 over-expression supports the hypothesis that expression of 
bcl-2 provides protection against cytotoxic drugs. Treatment 
with oracin (1.0 umol/l) significantly decreased the viability of 
control SV2 transfectants (Fig. 2A). This loss of viability was 
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Fig. 4. Progression of BL cells through the cell cycle phases in the absence and presence of oracin. DNA histograms of oracin-treated cells at 
24 h show accumulation in G2 phase. The 'sub-G2' peak representing the apoptotic cells is seen at 72 h incubation time. 
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significantly reduced in the bcl-2 transfectants. The sensitivity 
of SV2 cells was clearly demonstrated after exposure to 10 
μτηοΐ/ΐ oracin (Fig. 2B). Cell viability sharply decreased by 
2 orders of magnitude within 48 h after treatment while the 
bcl-2 viable cells remained nearly unaffected during the same 
period. However, unlike the 1.0 μιηοΐ/l condition, viable cell 
number sharply reduced on days 3 and 4. After the first 12 h 
of drug treatment, the level of apoptotic cells was unchanged 
in both cell lines (Fig. 3). A significant change in percentage of 
apoptotic cells in SV2 was observed 24 h after drug removal 
(26%), whereas bcl-2 transfected cells exhibited only basal 
level of apoptosis (6%). 72 h after removal of oracin the level 
of apoptosis in SV2 transfectants was approx. 70% and via-
bility of cell culture had fallen to 4% (Fig. 3). In contrast, the 
bcl-2 cells continued to show high cell viability (86%) and an 
unchanged level of apoptotic cells (7%). An increase in the 
size of cells treated with oracin in comparison with untreated 
cells was also observed after 24 h (data not shown). 
The DNA histograms of SV2 and bcl-2 cells exposed con-
tinuously to 1.0 umol/l of oracin together with the untreated 
control are shown in Fig. 4. Analysis of the cell-cycle profiles 
showed a significant decrease in the Gl cell population and an 
increase in the number of cells in the S and G2 phases after 6 h 
of oracin treatment. After 24 h most cells were arrested in G2 
with no significant changes in cell viability (82 and 93% for 
SV2 and bcl-2, respectively). After 72 h the viability of SV2 
culture had fallen to 5%, leading to the appearance of a sub-
population of reduced DNA stainability to the left of the G2 
peak on the PI histogram. This sub-G2 peak was a character-
istic of the SV2 cells but not of the bcl-2 cells, indicating that 
bcl-2 expression had protected transfected cells from dying by 
apoptosis after cell arrest in the G2 phase induced by oracin. 
The bcl-2 cells remained highly viable within the G2 phase at 
72 h with few cells actually dying by apoptosis. These cells 
eventually died after extended culture without progressing to 
mitosis. Cell size was increased as a consequence of arrest in 
the G2 phase of the cell cycle with a very close correlation 
between the two parameters (data not shown). The inability to 
recover from G2 arrest may be attributed to the lack of ability 
to repair DNA damage [17]. Similar results have been re-
ported in which X-ray irradiation of L929 and HL-60 cell 
fines resulted in G2 arrest accompanied by apoptosis and a 
reduced number of kinetochores in contrast to mitotic cells, 
suggesting processes different from those that operate in mi-
tosis [18]. It is interesting to mention that the Burkitt's lym-
phoma cells used in this study were also blocked in G2 phase 
after exposure to γ-irradiation but the bcl-2-rescued cells un-
derwent Gl arrest [19]. The progression of cells through mi-
tosis after exposure to cytotoxic agents has been suggested to 
be facilitated by the presence of functional p53, whereas p53-
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deficient cells are stalled in G2 thereby triggering apoptosis 
[20]. The BL cell lines are heterozygous-mutant with respect to 
the p53 configuration and therefore more likely to be p53-
deficient. Our results may therefore be in agreement with 
the finding of Wahl et. al. [20] that the loss of normal p53 
function has increased sensitivity to the anticancer agent pa-
clitaxel by increasing G2/M arrest and apoptosis. 
4. Conclusion 
The results indicate that oracin acts as a mitosis inhibitor 
and its site of action is probably at the G2 checkpoint. Arrest-
ing cells at this point can induce apoptosis which is prevented 
by the overexpression of bcl-2. bcl-2-rescued cells, however, 
do not progress through mitosis and consequently die after 
extended longevity which may be attributed to p53 deficiency. 
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